Categories for COVID-19/Coronavirus
Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The expanded collaboration will further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen (NL) site.
Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna.
In December 2020, the U.S. Environmental Protection Agency (EPA) released its proposed triennial updates to the Toxic Substances Control Act (TSCA) Fees Rule. SOCMA has responded to EPA's proposed TSCA fee revisions, addressing major aspects of the proposal.
As SOCMA continues to keep a pulse on the specialty and fine chemical industry, we understand that companies across the industry are grappling with how to encourage employee inoculations now that there’s increased availability of COVID-19 vaccines. We’ve spoken with leaders from Texas to Rhode Island and everywhere in between about how they are handling the vaccination within their companies, and here are a few takeaways you can consider when implementing your own plans.
With chemical safety, security and trade as crucial focal points for the specialty chemical value chain, the Society of Chemical Manufacturers & Affiliates (SOCMA) looks forward to continuing a robust dialogue and working with newly appointed Department of Homeland Security (DHS) Secretary Alejandro Mayorkas and Commerce Secretary Gina Raimondo on these key industry issues.
SOCMA has identified two EOs that will intersect with the work and activities of its Environmental, Health and Safety committee. Alongside our members, we are prepared to further our advocacy efforts through each agency's review and decision process.
Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.
2020 saw SOCMA’s Government Relations team continuing its efforts in support of the Specialty & Fine Chemical industry. With the... View Article
SOCMA member Lonza congratulates Moderna on interim Phase 3 clinical trial data.
Lonza announced today that the company has signed
an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.